
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>ACG Clinical Guideline: Perioperative Risk Assessment and Management in Patients With Cirrhosis</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>ACG Clinical Guideline: Perioperative Risk Assessment and Management in Patients With Cirrhosis</strong></summary>
            <div>
                <ul><li>Authors: Nadim Mahmud, Zachary P. Fricker, Lisa M. McElroy, Emad Qayed, Robert J. Wong, and George N. Ioannou.</li><li>Journal: American Journal of Gastroenterology.</li><li>Publication Date: September 3, 2025.</li><li>DOI: https://doi.org/10.14309/ajg.0000000000003616.</li><li>Focus: Comprehensive approach to perioperative risk assessment and management in patients w/ cirrhosis.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the proposed threshold for considering preoperative liver transplant evaluation based on postoperative mortality risk?</li><li>2. What are the 3 distinct categories of risk factors associated with adverse postoperative outcomes in cirrhosis?</li><li>3. What is the gold-standard method to assess portal pressure in cirrhosis?</li><li>4. What is the recommended daily protein intake for preoperative nutritional optimization in patients with cirrhosis?</li><li>5. Which bariatric surgery procedure is generally favored in patients with cirrhosis?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Preamble</strong></summary>
            <div>
                <ul><li>ACG Practice Parameters Committee formed expert writing group.</li><li>Regular meetings conducted to formulate PICO questions, develop recommendations, and perform GRADE assessments.</li><li>Electronic literature searches conducted in PubMed (MEDLINE), EMBASE, and Cochrane Library.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction</strong></summary>
            <div>
                <ul><li>Patients w/ cirrhosis have ↑ surgical risk relative to those w/o.</li><li>↑ prevalence of cirrhosis &amp; aging cohorts → ↑ cirrhosis surgeries.</li><li>Critical for clinicians to understand risk stratification &amp; perioperative risk reduction.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Risk Factors for Adverse Postoperative Outcomes in Patients With Cirrhosis</strong></summary>
            <div>
                <ul><li>Cirrhosis results in adverse surgical outcomes via complicated, multifactorial mechanisms.</li><li>Portal hypertension contributes to risk via multiple pathways.</li><li>Hematological abnormalities compound operative risk.</li></ul>
                
        <details>
            <summary><strong>Key Concepts</strong></summary>
            <div>
                <ul><li>Comprehensive evaluation requires consideration of liver-related factors, non-liver-related comorbidities, &amp; surgery-specific factors.</li><li>Individualized estimation is best accomplished by combining validated cirrhosis-specific surgical risk calculators w/ clinical judgment.</li><li>Validated cirrhosis-specific surgical risk calculators include relevant liver-related factors, non–liver-related comorbidities, and surgery-specific factors with clinical judgement and individual patient circumstances.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pathophysiological Basis</strong></summary>
            <div>
                <ul><li>Portal hypertension: ↑ risk of bleeding, impaired wound healing.</li><li>Malnutrition, frailty, sarcopenia: Impair wound healing &amp; physical recovery.</li><li>Hematological abnormalities: Thrombocytopenia interferes w/ hemostasis; disruptions in secondary hemostasis → bleeding/thrombosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Risk Prediction</strong></summary>
            <div>
                <ul><li>Accurate individualized predictions require cirrhosis-specific surgical risk calculators.</li><li>General scores (MELD-Na, CTP) are inadequate as they don&#x27;t incorporate surgical complexity/extrahepatic comorbidities.</li><li>Generic surgical risk calculators (ACS-NSQIP) are inadequate as they don&#x27;t include detailed measures of liver dysfunction.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>VOCAL-Penn Score</strong></summary>
            <div>
                <ul><li>Validated cirrhosis-specific model.</li><li>Uses 8 readily available factors.</li><li>Estimates postoperative mortality &amp; decompensation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Synthesis of Established Risk Factors</strong></summary>
            <div>
                <ul><li>Patients w/ very low MELD (6–9) &amp; CTP (5–6) scores &amp; no CSPH/hepatic decompensation have limited excess risk of adverse surgical events.</li><li>Cirrhosis increasingly diagnosed at early stages using noninvasive methods (elastography).</li><li>Recent guidelines emphasize compensated advanced chronic liver disease (cACLD) &amp; CSPH.</li></ul>
                
        <details>
            <summary><strong>MELD and CTP Scores</strong></summary>
            <div>
                <ul><li>Low MELD (6-9) and CTP (5-6) scores indicate limited excess surgical risk, especially for low-risk, elective surgeries.</li><li>Example: Elective umbilical hernia repair in patients w/ cirrhosis w/o ascites had low 30-day mortality (0.7%), but still &gt; noncirrhosis patients (0%).</li><li>Patients w/ cirrhosis &amp; MELD 6-9 undergoing abdominal surgery had low 30-day mortality (1.2%), but still &gt; noncirrhosis controls (0.8%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>cACLD and CSPH</strong></summary>
            <div>
                <ul><li>cACLD: Compensated Advanced Chronic Liver Disease.</li><li>CSPH: Clinically Significant Portal Hypertension.</li><li>Noninvasive diagnostic criteria based on liver stiffness &amp; platelet counts.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Noninvasive Criteria for cACLD</strong></summary>
            <div>
                <ul><li>LSM 10–14.9 kPa.</li><li>LSM 15–19.9 kPa w/ PLTs &gt;110 K/mm³.</li><li>LSM 20–24.9 kPa w/ PLTs &gt;150 K/mm³.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Portal Hypertension</strong></summary>
            <div>
                <ul><li>Degree of portal hypertension is one of the most important surgical risk factors.</li><li>Cirrhosis decompensation (ascites, encephalopathy, bleeding varices) &amp; clinical manifestations of CSPH (gastroesophageal varices w/o bleeding, portosystemic collaterals) are strongly associated w/ adverse postoperative outcomes.</li><li>HVPG is gold standard to assess portal pressure.</li></ul>
                
        <details>
            <summary><strong>Definitions</strong></summary>
            <div>
                <ul><li>Portal hypertension: HVPG ≥5 mm Hg.</li><li>CSPH: HVPG ≥10 mm Hg.</li><li>Clinical evidence of hepatic decompensation (ascites, encephalopathy, bleeding varices) = CSPH.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Noninvasive Definitions of CSPH</strong></summary>
            <div>
                <ul><li>LSM ≥25 kPa (irrespective of PLT count).</li><li>LSM 20–24.9 kPa w/ PLT count &lt;150 K/mm³.</li><li>LSM 15–19.9 kPa w/ PLT count &lt;110 K/mm³.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HVPG</strong></summary>
            <div>
                <ul><li>Independent predictor of outcomes after surgery in cirrhosis.</li><li>Predicts postoperative outcomes after hepatic resection.</li><li>Associated w/ ↑ risk of liver-related adverse events postoperatively in extrahepatic surgery.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hemostasis in Cirrhosis</strong></summary>
            <div>
                <ul><li>Cirrhosis affects both prothrombotic &amp; antithrombotic pathways.</li><li>Net effect on hemostasis not accurately reflected by PT/INR, aPTT, &amp; PLT count.</li><li>Very low PLT counts (e.g., &lt;50–75/μL) are independently associated w/ procedural bleeding &amp; adverse postoperative outcomes.</li></ul>
                
        <details>
            <summary><strong>Traditional Tests</strong></summary>
            <div>
                <ul><li>PT/INR, aPTT, &amp; PLT count do not accurately capture hemostatic balance in cirrhosis.</li><li>PT/INR not independently associated w/ procedural bleeding.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Thrombocytopenia</strong></summary>
            <div>
                <ul><li>Very low PLT counts (&lt;50/μL or &lt;75/μL) associated w/ ↑ bleeding risk.</li><li>Low PLT count may reflect ↑ severity of liver disease &amp; portal hypertension.</li><li>PLT count alone doesn&#x27;t precisely mirror PLT function.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Viscoelastic Testing</strong></summary>
            <div>
                <ul><li>TEG &amp; ROTEM provide global functional assessment of clot formation &amp; dissolution.</li><li>May be superior to PT/aPTT or PLT count for hemostatic balance assessment.</li><li>Insensitive to von Willebrand factor &amp; protein C; may underestimate hemostatic function.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Nonhepatic Comorbid Conditions</strong></summary>
            <div>
                <ul><li>Affect postoperative mortality in cirrhosis &amp; require independent assessment.</li><li>Overall measures of functional status &amp; comorbidity (ASA class, Charlson comorbidity index, older age) greatly affect postoperative mortality.</li><li>Individual chronic conditions (COPD, heart failure, cancer) &amp; acute conditions (sepsis, ventilator dependence) affect postoperative mortality.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Malnutrition, Sarcopenia, and Frailty</strong></summary>
            <div>
                <ul><li>Very common &amp; potentially modifiable risk factors for adverse postoperative outcomes in cirrhosis.</li><li>Prevalence of malnutrition (&gt;80%) &amp; sarcopenia (25%–70%) is very high.</li><li>Sarcopenia (assessed by imaging, bioimpedance, or anthropometry) can occur even in normal/↑ BMI.</li></ul>
                
        <details>
            <summary><strong>Frailty</strong></summary>
            <div>
                <ul><li>Defined as a clinical state of ↓ physiological reserve &amp; ↑ vulnerability to health stressors.</li><li>Associated w/ adverse postoperative outcomes.</li><li>Assessed by diagnostic codes (VA Frailty index, Hospital Frailty Risk Score) or frailty tests (Liver Frailty Index).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Preoperative Evaluation</strong></summary>
            <div>
                <ul><li>Noninvasive fibrosis assessment to identify advanced fibrosis/cirrhosis.</li><li>Applying prognostic models for cirrhosis surgical risk.</li><li>Preoperative assessment for CSPH.</li></ul>
                
        <details>
            <summary><strong>Noninvasive Fibrosis Assessment</strong></summary>
            <div>
                <ul><li>In patients w/ known/suspected chronic liver disease w/o cirrhosis diagnosis, assess hepatic fibrosis.</li><li>Fibrosis staging via biomarker panels (FIB-4) or elastography (VCTE, US, MRI).</li><li>Tests have adequate negative predictive value for excluding advanced fibrosis/cirrhosis.</li></ul>
                
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>In patients w/ known liver disease but unknown fibrosis stage, FIB-4 &amp;/or elastography may be used to identify patients likely to have advanced fibrosis/cirrhosis, impacting surgical planning &amp; perioperative management.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Decision Making</strong></summary>
            <div>
                <ul><li>If surgical plans/patient counseling wouldn&#x27;t change w/ new cirrhosis diagnosis, no need for preoperative assessment for hepatic fibrosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Prognostic Models for Cirrhosis Surgical Risk</strong></summary>
            <div>
                <ul><li>Assessment requires understanding of liver disease severity, nonhepatic comorbid factors, &amp; surgery risks.</li><li>Perioperative risk ↑ w/ liver disease severity (CTP, MELD, ALBI, Chronic Liver Failure-Consortium).</li><li>Models use lab &amp; clinical data to assess liver function (INR, albumin) &amp; portal hypertension severity (PLT count).</li></ul>
                
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>Cirrhosis-specific risk scores (MELD, CTP, Mayo, VOCAL-Penn Score) are useful to estimate operative risk &amp; facilitate shared decision-making. Each has benefits &amp; limitations.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Mayo Surgical Risk Score</strong></summary>
            <div>
                <ul><li>Accounts for liver disease severity &amp; nonhepatic comorbidities (age, ASA classification).</li><li>Has become progressively miscalibrated &amp; overestimates surgical risk.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>VOCAL-Penn Score</strong></summary>
            <div>
                <ul><li>Most recently developed &amp; adopted cirrhosis surgical risk calculator.</li><li>Incorporates surgery type into risk predictions.</li><li>Predicts postoperative decompensation through 90 days.</li><li>Applicable to both nonhepatic &amp; liver-specific surgeries.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Model Performance</strong></summary>
            <div>
                <ul><li>VOCAL-Penn Score&#x27;s predictive ability exceeds Mayo Surgical Risk Score in discrimination, calibration, &amp; overall performance.</li><li>Scores should never be used in isolation from clinical judgment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Preoperative Assessment for CSPH</strong></summary>
            <div>
                <ul><li>CSPH has important prognostic implications for liver-related adverse postoperative events.</li><li>Proposed noninvasive criteria for CSPH are useful in predicting postoperative outcomes in hepatectomy.</li><li>Patients w/ LSM between ~14 &amp; 25 kPa w/o decompensation may benefit from HVPG measurement if confirmation of absence of CSPH would change management.</li></ul>
                
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>In patients w/ compensated cirrhosis &amp; unclear CSPH, suggest LSM &amp; PLT count assessment to rule in CSPH using recommended thresholds, &amp; cross-sectional imaging to identify portosystemic collaterals &amp;/or complications of portal hypertension (conditional recommendation, very low quality of evidence).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Liver Transplant Evaluation Before Elective Surgery</strong></summary>
            <div>
                <ul><li>No standardized criteria to prompt liver transplant evaluation before surgery in cirrhosis.</li><li>Previous guidance recommended considering evaluation in patients w/ projected 90-day mortality &gt;15%.</li><li>Transplant listing only occurs in patients w/o contraindications (unmodifiable cardiovascular/psychosocial comorbidities).</li></ul>
                
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>In selected patients w/ cirrhosis undergoing elective surgery, preoperative liver transplant evaluation can allow for potential life-saving transplant in the event of postoperative decompensation. A proposed threshold to prompt consideration of preoperative liver transplant evaluation is a projected 90-day postoperative mortality risk of &gt;15%, which may be estimated from tools such as the VOCAL-Penn Score.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Emergency Surgery</strong></summary>
            <div>
                <ul><li>Patients needing emergency surgery might not have time for preoperative transplant evaluation.</li><li>Discuss potential transplant candidacy if concern for major risk of postoperative decompensation.</li><li>Consultation w/ or transfer to a center that offers liver transplant may permit expedited evaluation postoperatively.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>High-Risk Elective Surgery</strong></summary>
            <div>
                <ul><li>Complete transplant evaluation preoperatively to avoid extensive testing during postoperative decline.</li><li>Knowledge of suitability for transplant may inform decision-making by patients &amp; providers before high-risk surgery.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Assessment of Preoperative Frailty</strong></summary>
            <div>
                <ul><li>Assessment of frailty using Hospital Frailty Risk Score improved prediction of postoperative mortality in cirrhosis undergoing extrahepatic surgery vs MELD alone.</li><li>Unclear if in-person assessments of frailty using cirrhosis-specific instruments (liver frailty index) may improve risk stratification.</li></ul>
                
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>Preoperative assessment of frailty in patients with cirrhosis may help to inform surgical risk.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Risk Mitigation Strategies and Perioperative Management</strong></summary>
            <div>
                <ul><li>Consider modifiable risk factors &amp; interventions to reduce postoperative mortality &amp; morbidity.</li><li>Interventions: Treatment of reversible liver disease, lifestyle changes, correction of hemostatic derangements, medical optimization of cirrhosis-related decompensation, measures to reduce portal hypertension.</li></ul>
                
        <details>
            <summary><strong>Treatment of Underlying Liver Disease</strong></summary>
            <div>
                <ul><li>Patients w/ decompensated cirrhosis or reversible hepatic insults (active alcohol use, hepatitis B/C, autoimmune hepatitis) should receive treatment before elective surgery to improve liver function.</li><li>Multidisciplinary consultation between Surgery, Anesthesiology, &amp; Hepatology teams.</li></ul>
                
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>Treatment of reversible hepatic insults as drivers of liver disease (e.g., hepatitis B, hepatitis C, autoimmune hepatitis, etc.) in advance of elective surgery may mitigate operative risk.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Alcohol and Tobacco Cessation</strong></summary>
            <div>
                <ul><li>Adverse impacts of preoperative alcohol use are well established in general surgical populations.</li><li>Alcohol use in cirrhosis has deleterious effects on liver function &amp; portal hypertension.</li><li>Active preoperative alcohol consumption associated w/ ↑ risk of infection (RR 1.73), wound complications (RR 1.23), ICU admission (RR 1.29), &amp; prolonged length of stay (RR 1.24).</li></ul>
                
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>Strict alcohol and tobacco cessation in patients with cirrhosis being considered for elective surgery may reduce the risk of liver-related adverse events and postoperative complications including infection, wound complications, and need for intensive care unit (ICU) admission.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Tobacco Use</strong></summary>
            <div>
                <ul><li>Preoperative tobacco use is an independent risk factor for liver-related complications in liver resection for HCC.</li><li>Concomitant tobacco &amp; preoperative alcohol use demonstrate synergistic ↑ in postoperative risk.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Nutritional Optimization</strong></summary>
            <div>
                <ul><li>Limited data suggest perioperative nutritional support initiated 14 days before surgery may reduce major postoperative morbidity rates (RR 0.66).</li><li>Patients should consume ≥30–35 kcal/kg calories per day &amp; 1.25–1.5 g/kg per day of protein, calculated based on ideal body weight.</li><li>Protein intake should not be restricted in patients w/ hepatic encephalopathy.</li></ul>
                
        <details>
            <summary><strong>Key Concepts</strong></summary>
            <div>
                <ul><li>Preoperative nutritional optimization in patients with cirrhosis includes high-calorie (30–35 kcal/kg/d) and high-protein (1.25–1.5 g/kg/d) intake, initiated ideally at least 2 weeks prior to surgery. Nutritional consultation and nasoenteric feeding may be required in some patients who have difficulty in achieving these goals.</li><li>In patients with cirrhosis-related frailty and sarcopenia, prehabilitation programs may be considered prior to elective surgery. Improved functional status may reduce risk of postoperative complications.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Late Evening Snack</strong></summary>
            <div>
                <ul><li>May improve total body protein status by shortening periods of nocturnal fasting.</li><li>Preoperative nutrition consultation &amp; nasoenteric tube placement may be needed.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Prehabilitation Programs</strong></summary>
            <div>
                <ul><li>Designed to improve preoperative exercise capacity &amp; functional status.</li><li>Demonstrated to ↓ incidence of postoperative complications &amp; reduce healthcare utilization in heterogeneous cohorts.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Hemostatic Derangements</strong></summary>
            <div>
                <ul><li>Derangements in hemostatic parameters are common in cirrhosis.</li><li>Data evaluating bleeding risk as a function of preoperative PLT count are mixed.</li><li>Several prospective studies found no difference in periprocedural bleeding related to PLT count.</li></ul>
                
        <details>
            <summary><strong>Key Concepts</strong></summary>
            <div>
                <ul><li>If available, viscoelastic testing such as TEG may be considered to guide management of coagulopathy in the perioperative setting for patients with cirrhosis rather than reliance on traditional hemostatic markers alone to minimize periprocedural bleeding risk.</li><li>If viscoelastic testing is not available, it is reasonable to correct severe thrombocytopenia (&lt;50 K/mm³) in patients with cirrhosis prior to major surgery.</li><li>Use of vitamin K or blood products to correct elevated INR prior to major surgery has not been demonstrated to reduce bleeding risk in patients with cirrhosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Vitamin K</strong></summary>
            <div>
                <ul><li>Vitamin K administration has not been studied in the preoperative setting.</li><li>Routine use does not reduce the risk of bleeding in hospitalized patients w/ cirrhosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Viscoelastic Testing (TEG/ROTEM)</strong></summary>
            <div>
                <ul><li>May be a superior tool to guide transfusion vs traditional hemostatic parameters.</li><li>RCTs &amp; meta-analysis demonstrated reduced utilization of blood product transfusions w/o ↑ incidence of bleeding when TEG was evaluated.</li><li>TEG-guided transfusion approach would reduce unnecessary transfusions.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Use of Thrombopoietin Receptor Agonists</strong></summary>
            <div>
                <ul><li>TPO receptor agonists (avatrombopag, eltrombopag) are effective in transiently raising PLT count.</li><li>Studied in patients w/ cirrhosis &amp; thrombocytopenia undergoing elective invasive procedures.</li><li>Eltrombopag (75 mg daily for 14 days) ↓ likelihood of PLT transfusion vs placebo (28% vs 81%).</li></ul>
                
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>In patients with cirrhosis and severe thrombocytopenia (&lt;50,000 K/mm³) undergoing invasive procedures, we recommend thrombopoietin (TPO) receptor agonists dosed according to baseline PLT count to reduce the need for perioperative transfusions and potentially reduce the risk of bleeding (strong recommendation, moderate quality of evidence).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Avatrombopag</strong></summary>
            <div>
                <ul><li>5-day course (60 mg daily for baseline PLT &lt;40 K/mm³ or 40 mg daily for baseline PLT 40–50 K/mm³) demonstrated significant ↓ in PLT transfusion vs placebo.</li><li>No ↑ risk of thrombotic adverse events.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis</strong></summary>
            <div>
                <ul><li>Use of TPO receptor agonists in patients w/ cirrhosis &amp; PLT &lt;50 K/mm³ significantly associated w/ ↑ preoperative PLT count, ↓ incidence of PLT transfusions (22.5% vs 67.8%), &amp; ↓ incidence of periprocedural bleeding (11.6% vs 15.6%).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Role of Preoperative TIPS</strong></summary>
            <div>
                <ul><li>Patients w/ cirrhosis undergoing major abdominal/thoracic cavity surgeries are susceptible to portal hypertension-related risks of bleeding.</li><li>Preoperative TIPS is a candidate intervention to mitigate this risk.</li><li>Data on this practice are mixed; no prospective studies/trials to inform a robust evidence base.</li></ul>
                
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>In patients with cirrhosis and CSPH with alternative indications for transjugular intrahepatic portosystemic shunt (TIPS; e.g., refractory ascites), we suggest preoperative TIPS to reduce postoperative morbidity and mortality attributable to portal hypertension (conditional recommendation, very low quality of evidence).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recent Studies</strong></summary>
            <div>
                <ul><li>Chang et al reported lower rates of postoperative acute-on-chronic liver failure in patients w/ cirrhosis undergoing diverse surgeries who received preoperative TIPS (9% vs 29% at 28 days).</li><li>Piecha et al demonstrated lower in-hospital mortality &amp; need for liver transplant after both low- &amp; high-risk surgeries in patients w/ preoperative TIPS (19% vs 40%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Limitations</strong></summary>
            <div>
                <ul><li>Studies were single-center; concerns remain regarding potential residual confounding.</li><li>In a recent study, preoperative TIPS patients had evidence of worsened liver synthetic function immediately before surgery &amp; ↑ hazard of postoperative mortality.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Considerations</strong></summary>
            <div>
                <ul><li>Utilization of preoperative TIPS should be limited to experienced centers &amp; decided on a patient-by-patient basis through multidisciplinary discussion.</li><li>Alternative indications for TIPS (large varices &amp; previous variceal bleeding or refractory ascites) &amp; contraindications (refractory hepatic encephalopathy) should be considered.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Performance of Surgery at an Experienced Center</strong></summary>
            <div>
                <ul><li>Surgery performed at high-volume &amp;/or transplant centers may lead to improved outcomes.</li><li>Data largely focused on hepatic surgery.</li><li>High-volume centers ($10 hepatectomies per year) had higher adjusted 10-year survival rate vs low-volume centers (28.7% vs 25.1%).</li></ul>
                
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>In patients with cirrhosis undergoing major hepatic surgery, we suggest referral to a high-volume liver surgery and/or transplant center, when feasible (conditional recommendation, very low quality of evidence).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>In patients with cirrhosis in need of a nonhepatic elective major surgery, referral to a high-volume liver surgery and/or transplant center, when feasible, may improve postoperative outcomes.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>High-Volume Centers</strong></summary>
            <div>
                <ul><li>High-volume centers ($25 hepatectomies per year) had significantly lower odds of in-hospital mortality relative to lower-volume centers (OR 0.79).</li><li>National Inpatient Sample analyses &amp; multicenter Italian cohort reported similar findings.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Nonhepatic Surgeries</strong></summary>
            <div>
                <ul><li>National Inpatient Sample analysis of patients w/ cirrhosis undergoing orthopedic procedures demonstrated an inverse relationship between hospital cirrhosis volume &amp; in-hospital mortality.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Preoperative Management of Cirrhosis-Related Decompensations</strong></summary>
            <div>
                <ul><li>Limited data evaluating perioperative management of cirrhosis decompensations.</li><li>Ascites should be preoperatively sampled to rule out SBP.</li><li>Active SBP should prompt delay of elective surgery until antibiotics completed.</li></ul>
                
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>Remaining current with routine cirrhosis-related management prior to elective surgery, including hepatocellular carcinoma screening, optimization of ascites and hepatic encephalopathy, variceal screening and/or bleeding prophylaxis, and spontaneous bacterial peritonitis (SBP) prophylaxis when indicated, may mitigate operative risk.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>SBP Prophylaxis</strong></summary>
            <div>
                <ul><li>Review indications for SBP prophylaxis, including previous SBP &amp; low-protein ascites (&lt;1.5 g/L) w/ concomitant renal dysfunction or liver failure.</li><li>Large-volume ascites should be preoperatively drained (albumin 6–8 g/L should be given if &gt;5 L is removed) &amp; actively managed postoperatively.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hepatic Encephalopathy</strong></summary>
            <div>
                <ul><li>Patients w/ hepatic encephalopathy should have lactulose &amp;/or rifaximin continued through the perioperative period.</li><li>Close attention to serum sodium &amp; minimization of medications that may exacerbate encephalopathy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Nonselective Beta Blockers (NSBBs)</strong></summary>
            <div>
                <ul><li>Patients taking NSBBs for CSPH or secondary prevention of esophageal variceal bleeding should continue these medications in the peri-operative period, provided that the systolic blood pressure is over 90 mm Hg.</li><li>Upper endoscopy should be performed &amp; NSBBs or band ligation pursued for large varices or medium varices w/ high-risk stigmata.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hepatocellular Carcinoma Screening</strong></summary>
            <div>
                <ul><li>Should be up-to-date, as diagnosis of liver cancer may affect surgical decision-making &amp; transplant consideration.</li><li>Patients w/ recent outpatient gastroenterology/hepatology visits (along w/ active management of cirrhosis-related medications &amp; paracentesis) before surgery have lower postoperative mortality.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Surgery-Specific Considerations</strong></summary>
            <div>
                <ul><li>Specific surgical scenarios uniquely affected by cirrhosis.</li><li>Abdominal hernia repair.</li><li>Cholecystectomy.</li></ul>
                
        <details>
            <summary><strong>Abdominal Hernia Repair</strong></summary>
            <div>
                <ul><li>Prevalence of abdominal hernia can reach up to 40% in patients w/ decompensated cirrhosis.</li><li>Management often deferred due to hemostatic derangements, CSPH, refractory ascites, &amp;/or malnutrition/sarcopenia.</li><li>Deferring operative repair ↑ risk of complications requiring emergent repair.</li></ul>
                
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>In patients with cirrhosis and abdominal hernia, surgical consultation after optimizing ascites control for elective repair may reduce risk of hernia complications such as incarceration or spontaneous rupture that would require higher-risk emergent repair.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>CRUCIAL Trial</strong></summary>
            <div>
                <ul><li>No significant difference in time to minor/major complications between elective repair &amp; conservative management through 2-year follow-up (overall complication rate 64.7%).</li><li>Recurrent hernia occurred in 16.7% of those who underwent repair.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Systematic Review</strong></summary>
            <div>
                <ul><li>↑ risk of mortality in patients w/ cirrhosis (OR 8.50); much of the ↑ risk attributed to emergent hernia repair.</li><li>Emergency hernia repair had significantly higher 30-day mortality than elective repair (12.2% vs 1.2%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Ascites Control</strong></summary>
            <div>
                <ul><li>Of particular importance in patients w/ cirrhosis undergoing elective hernia repair.</li><li>Inadequate control ↑ risk of wound complications &amp; hernia recurrence.</li><li>Approach to ascites control should follow standard management algorithms for decompensated cirrhosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Cholecystectomy</strong></summary>
            <div>
                <ul><li>Prevalence of cholelithiasis is ~2-fold higher in patients w/ cirrhosis.</li><li>Patients w/ asymptomatic cholelithiasis should not be treated.</li><li>In CTP A &amp; B cirrhosis, indications for elective cholecystectomy are the same as in patients w/o cirrhosis; laparoscopic cholecystectomy remains the procedure of choice.</li></ul>
                
        <details>
            <summary><strong>Key Concept</strong></summary>
            <div>
                <ul><li>In patients with cirrhosis and indications for cholecystectomy, laparoscopic cholecystectomy is generally favored in CTP A and B cirrhosis, whereas most patients with CTP class C cirrhosis have prohibitive cholecystectomy risk and may benefit from supportive care and alternative drainage procedures (e.g., percutaneous cholecystectomy, endoscopic drainage, gallbladder aspiration) if available. The VOCAL-Penn score may be used to provide individualized estimates of postoperative risk in cases of high concern or uncertainty.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Acute Cholecystitis</strong></summary>
            <div>
                <ul><li>Antibiotics &amp; cholecystectomy are the standard of care.</li><li>Laparoscopic cholecystectomy is generally safe in CTP A &amp; B cirrhosis, but associated w/ significantly higher rates of postoperative complications &amp; mortality in CTP class C disease.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Alternative Procedures</strong></summary>
            <div>
                <ul><li>Patients w/ prohibitive surgical risk should be initially treated w/ antibiotics.</li><li>Percutaneous cholecystostomy, transpapillary drainage, &amp; endoscopic ultrasound-guided transmural gallbladder drainage are alternative procedural options.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Common Bile Duct Stones</strong></summary>
            <div>
                <ul><li>Endoscopic sphincterotomy or balloon extraction is preferable to laparoscopic or open common bile duct exploration.</li><li>Risks of postsphincterotomy bleeding &amp; pancreatitis are elevated in patients w/ cirrhosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Cardiac Surgery</strong></summary>
            <div>
                <ul><li>Very little data related to cardiac surgery in patients w/ cirrhosis; operative risk ↑ w/ liver disease severity.</li><li>Postoperative mortality rates were 0%–11%, 18%–50%, &amp; 67%–100% in CTP A, B, &amp; C patients, respectively.</li><li>High degrees of study heterogeneity prevented analysis of specific surgical indications or the role of various anesthetic or surgical techniques in mitigating adverse outcomes.</li></ul>
                
        <details>
            <summary><strong>CASTER Study</strong></summary>
            <div>
                <ul><li>Retrospective observational cohort study of 144 adults w/ CTP A or B cirrhosis who underwent cardiac surgery.</li><li>Procedures included coronary artery bypass grafting (36%), valvular surgery (50%), &amp; aortic procedures (14%).</li><li>Perioperative complications &amp; in-hospital mortality were higher in CTP B vs A cirrhosis (20% vs 13%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>EuroSCORE</strong></summary>
            <div>
                <ul><li>Predicts mortality after cardiac surgery; liver function not included in the score.</li><li>EuroSCORE II showed poor predictive value for patients w/ Child B &amp; C cirrhosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Ascites</strong></summary>
            <div>
                <ul><li>Poor prognostic sign.</li><li>Transfusion requirement, acute kidney injury, ICU stay &gt;72 hours, &amp; need for tracheostomy were all higher in patients w/ ascites.</li><li>30-day mortality rate was significantly higher in the ascites group than in the nonascites group (35.7% vs 5.5%).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Bariatric Surgery</strong></summary>
            <div>
                <ul><li>Considered a safe &amp; effective treatment for obesity in selected patients w/ cirrhosis.</li><li>Median excess weight loss of 60.44% in adults w/ compensated cirrhosis &amp; remission of metabolic comorbidities in &gt;50% of patients.</li><li>Mortality rates were significantly higher in patients w/ decompensated vs compensated cirrhosis (18.2% vs 0.9%).</li></ul>
                
        <details>
            <summary><strong>Key Concepts</strong></summary>
            <div>
                <ul><li>Bariatric surgery can be safely performed in selected patients with well-compensated cirrhosis. Laparoscopic sleeve gastrectomy is the procedure of choice.</li><li>In liver transplant candidates with indications for bariatric surgery, sleeve gastrectomy prior to transplantation or at the time of transplantation may be considered based on center expertise. There are limited data to support bariatric surgery after liver transplantation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Laparoscopic Sleeve Gastrectomy</strong></summary>
            <div>
                <ul><li>Increasingly recognized as the bariatric modality of choice in patients w/ cirrhosis.</li><li>Shorter operating time &amp; allows access to the remnant stomach &amp; biliary system.</li><li>Reduces risk of malabsorption or placement of a foreign body but may predispose to bleeding risk in the setting of gastric varices.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Roux-en-Y Gastric Bypass (RYGB)</strong></summary>
            <div>
                <ul><li>Provides the greatest overall &amp; long-term weight loss but might have a greater risk of vitamin deficiencies that may exacerbate hepatic dysfunction.</li><li>Prevents native endoscopic access to the stomach or biliary tree in cases of a gastrointestinal bleed or biliary complications.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastric Banding</strong></summary>
            <div>
                <ul><li>Least invasive procedure, but has the lowest efficacy related to long-term weight loss &amp; adds a potential risk of infection w/ placement of a foreign device.</li><li>Infrequently performed in modern practice.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Liver Transplantation Candidates</strong></summary>
            <div>
                <ul><li>Sleeve gastrectomy is the preferred approach as it preserves endoscopic access to the biliarytree, avoids malabsorption-related issues for immunosuppression medications, &amp; poses less operative risk vs RYGB.</li><li>Bariatric surgery before liver transplant is generally safe in patients w/ low MELD scores &amp; compensated cirrhosis; should be performed at an experienced, high-volume center.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Bariatric Surgery Timing</strong></summary>
            <div>
                <ul><li>Weight loss may mitigate some transplant-related surgical risk, ↑ transplant access, &amp; minimize risk of post-transplant recurrent metabolic dysfunction–associated steatohepatitis.</li><li>Bariatric surgery at the time of liver transplant may be considered in selected patients at experienced centers.</li><li>Bariatric surgery after liver transplant avoids surgical risk related to cirrhosis; however, it does not modify the problem of morbid obesity during waitlisting or the perioperative transplant period.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>Surgical decision-making in patients w/ cirrhosis requires a nuanced, multidisciplinary approach.</li><li>Accounts for liver disease severity, portal hypertension, non-hepatic comorbidities, &amp; nature/setting of the planned procedure.</li><li>Evidence-based recommendations &amp; key concepts support individualized preoperative risk assessment &amp; perioperative optimization.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
